13.06.2024 - ~ Alerts CEO of Errors by Staff in the Determination for Company Additions ~ ~ Despite Repeated Requests by Rumble, LSEG Failed to Address Obvious Errors in Calculations ~ ~ Refusal to Correct Obvious Errors Does a Disservice to all Investors in .
SAN DIEGO, CA / ACCESSWIRE / May 28, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical stage pharmaceutical company developing innovative solutions for severe pain
Ensysce Biosciences Regains Compliance with Nasdaq bignewsnetwork.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bignewsnetwork.com Daily Mail and Mail on Sunday newspapers.